surmount 2 tirzepatide ECO 2026: SURMOUNT-MAINTAIN proves sustains weight loss long term Clinical Trial Talks: Surmount 2

GLP-1 receptor agonists such as Ozempic (semaglutide) and Trulicity (dulaglutide) have become massively popular drugs for the management of weight, diabetes, and cardiovascular health

How can marketers avoid overhyping GLP1 therapies

7 Although a phase 3 trial (BEACON) was terminated due to cardiovascular safety concerns, Nrf2 activation still remains a potential therapeutic target for DN patients

Avoid products making disease treatment claims like cures liver disease, detoxifies heavy metals, or treats Parkinsonsthose are prohibited drug claims

Hypoglycemia was uncommon and primarily limited to participants with type 2 diabetes who were taking concomitant diabetes medications known to cause hypoglycemia (sulfonylureas, insulin), rather than being caused by retatrutide itself

Patients often experience significant reductions in HbA1c, a marker of long-term blood sugar control, often surpassing the improvements seen with other diabetes medications